• Molecular NameCyclizine
  • SynonymCiclizina [INN-Spanish]; Cyclizine Chloride; Cyclizine Hydrochloride; Cyclizinum [INN-Latin]
  • Weight266.388
  • Drugbank_IDDB01176
  • ACS_NO82-92-8
  • Show 3D model
  • LogP (experiment)3.97
  • LogP (predicted, AB/LogP v2.0)3.34
  • pka2.4, 7.8
  • LogD (pH=7, predicted)2.02
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.28
  • LogSw (predicted, AB/LogsW2.0)0.86
  • Sw (mg/ml) (predicted, ACD/Labs)2.97
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds3
  • TPSA6.48
  • StatusFDA approved; US withdrawn
  • AdministrationOral, IM, IV, insufflation
  • PharmacologyA piperazine derivative with histamine H1-receptor antagonist (antihistamine) activity.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding60.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN-demethylated to inactive norcyclizine
  • Half life24 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A